Shares of VIVUS were up 10.5% today, after news that sales were up for November for the company's obesity drug, Qsymia. This may suggest that some of the company's new marketing strategies for the drug may be turning sluggish sales around. But is the drug finally gaining momentum, or is it just a volatile cyclical stock at the moment? Motley Fool health care analyst Max Macaluso gives us his thoughts on how and when we'll know where VIVUS is headed.
The potential market for obesity drugs is massive, but so are the risks. If you're looking for more information on the top two obesity-drug players, grab copies of our premium research reports on and VIVUS today. In the reports, our senior biotech analyst, Brian Orelli, Ph.D., breaks down each company's strengths and weaknesses, and explains the critical issues you need to know about. News in this space moves fast, so both reports come with a full year of updates. Click now for exclusive information on Arena and VIVUS.
The article Hold Your Horses, VIVUS Investors originally appeared on Fool.com.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.